Cargando…
The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
SIMPLE SUMMARY: Enfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with chemotherapy and immunotherapy. In this report, we looked at the extent of EV wastage (i.e., discarding of leftover drug not administered to the patient) in a single institute a...
Autores principales: | Sarfaty, Michal, Moore, Assaf, Regazzi, Ashley M., Mitchell, Aaron P., Rosenberg, Jonathan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657095/ https://www.ncbi.nlm.nih.gov/pubmed/34885086 http://dx.doi.org/10.3390/cancers13235977 |
Ejemplares similares
-
Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020) -
Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023) -
Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020) -
Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022) -
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)